An observational study in Chronic Heart Failure, sponsored by National Medical Research Center for Cardiology, Ministry of Health of Russian Federation. Recruiting at 1 site in Russia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by National Medical Research Center for Cardiology, Ministry of Health of Russian Federation · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Heart Failure with a site in Russia — 9 open to participants now, 10 under way, none of them phase 3. Heart Failure · Russia.
Among the 25 studies in Heart Failure with a site in Russia, this one is the 2nd largest by planned enrollment of the 10 observational ones that give a count, is the only one that started in 2024, is one of 10 observational ones, and was the 19th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →9 of the 25 studies in Heart Failure with a site in Russia are open now. Recruiting first, the newest first:
Pyatigorsk City Clinical Hospital Number 1 · Sites in Russia
Ages 18+
Tomsk National Research Medical Center of the Russian Academy of Sciences · Sites in Russia
National Medical Research Center for Therapy and Preventive Medicine · Sites in Russia
Ages 50–70
Meshalkin Research Institute of Pathology of Circulation · Sites in Russia
Ages 18–75
I.M. Sechenov First Moscow State Medical University · Sites in Russia
Ages 18+
A study can be open while its sites in Russia have not opened yet or have stopped. Only those recruiting at a site in Russia →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 5 · Phase 4 1
First in 2005; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20,000 is above the median of 200 across 1,987 observational studies indexed under Heart Failure.
Median enrollment 66 across the 15 interventional studies, 250 across the 10 observational. Of the 15 that completed or were terminated, 5 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 25 have an industry lead sponsor. The 10 most frequent:
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation is the lead sponsor of 20 studies on the registry; 11 are open to participants now.
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation has 5 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
5 of the studies in Heart Failure with a site in Russia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05770349Tomsk National Research Medical Center of the Russian Academy of SciencesUltrastructural Characteristics of Mitochondria in Cardiomyocytes in Heart Failure | 2026-11 |
| NCT07375433National Medical Research Center for Therapy and Preventive MedicineHeart Failure With Preserved Ejection Fraction in Patients With Сhronic Obstructive Pulmonary Disease: Clinical Course and Prognosis | 2026-12-31 |
| NCT07480915Tomsk National Research Medical Center of the Russian Academy of SciencesRisk Stratification of MACE in Heart Failure Patients Who Undergoing CABG | 2027-03 |
| NCT07372196Meshalkin Research Institute of Pathology of CirculationLeft Bundle Branch Pacing in Patients With Hypertrophic Cardiomyopathy After Myectomy | 2027-05-01 |
| NCT07552142I.M. Sechenov First Moscow State Medical UniversityPatient-Reported Health Status Assessment Using the KCCQ for Early Detection of Heart Failure Worsening | 2027-10-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 25 studies in Heart Failure with a site in Russia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A prospective-retrospective observational registry of patients diagnosed with chronic heart failure in the regions of the Russian Federation.
The study is non-interventional and does not involve any interventions in clinical practice, the choice of treatment methods (including the type of medical device used and the method of surgical intervention) and examination.
A control observation group is not intended.
The study will include retrospective and prospective data of patients with an outpatient or inpatient diagnosis of CHF.
The duration of the observation period of an individual patient with CHF is limited by the study period, or the patient's death, and includes the studied retrospective and dynamic prospective parameters. Prospective data of CHF (any stage and FC) subjects are planned to be included sequentially as they appear in inpatient CHF centers and outpatient CHF offices until 12/31/2027 inclusive and further upon extension of the study.
Retrospective data will be provided by chief freelance cardiologists of 33 constituent entities of the Russian Federation (Central Federal District, Ural Federal District, Siberian Federal District, Far Eastern Federal District) (individually, according to agreement)
At least 3% of CHF subjects in the target regions of Russia will be included in that trial by performing thier medical records analysis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Age of subjects with different phenotypes and stages of CHF
Time frame: Every 12 months, up to 3 years
Female to male sex ratio of subjects with different phenotypes and stages of CHF
Time frame: Every 12 months, up to 3 years
Clinical status of subjects with different phenotypes and stages of CHF
Time frame: Every 12 months, up to 3 years
Proportion of employable and working subjects with different phenotypes and stages of CHF
Time frame: Every 12 months, up to 3 years
The proportion of subjects with different algorithms for diagnosing CHF and the proportion of subjects with a verified diagnosis of CHF (established according to the recommended algorithm for diagnosing CHF)
Time frame: Every 12 months, up to 3 years
The proportion of subjects taking drugs of each class and all four classes of the recommended four-component therapy regimen (in the overall choice and in different phenotypes of CHF; working/non-working age; working/non-working)
Time frame: Every 12 months, up to 3 years
Number and proportion of subjects with wearable devices when using an online tool for identifying subjects with CHF with indications for high-tech medical care
Time frame: Every 12 months, up to 3 years
Number and proportion of subjects when using an online tool for identifying subjects with CHF with indications for high-tech medical care
Time frame: Every 12 months, up to 3 years
Proportions of subjects with an increase in EF ≥10% and a decrease in the functional class of CHF by 1 point
Time frame: Every 12 months, up to 3 years
The proportion of subjects hospitalized for decompensated CHF in the departments of therapeutic and cardiology profiles *
Time frame: Every 12 months, up to 3 years
Proportion of subjects with newly diagnosed type 2 diabetes*
Time frame: Every 12 months
Proportion of subjects with deterioration of renal function*
Time frame: Every 12 months, up to 3 years
Proportion of subjects with newly diagnosed malignant neoplasm*
Time frame: Every 12 months, up to 3 years
Proportion of subjects who died from CV causes*
Time frame: Every 12 months, up to 3 years
Proportion of subjects with different causes of death*
Time frame: Every 12 months, up to 3 years
Incidence and event rates (per 100 subject-years) for hospitalizations due to HF*
Time frame: Every 12 months, up to 3 years
Incidence and event rates (per 100 subject-years) for death from CV causes*
Time frame: Every 12 months, up to 3 years
Incidence and event rates (per 100 subject-years) for death from any cause*
Time frame: Every 12 months, up to 3 years
The proportion of subjects with preferential drug provision for cardiovascular disease, diabetes mellitus*
Time frame: Every 12 months, up to 3 years
Average frequency of outpatient visits of subjects with CHF to medical institutions*
Time frame: Every 12 months, up to 3 years
The proportion of subjects registered with a cardiologist or therapist with different phenotypes and stages of CHF*
Time frame: Every 12 months, up to 3 years
Average frequency of telephone patronage *
\*- in the overall sample and in groups of subjects with HFrEF, HFmrEF, HFpEF and in different age categories (18-49 years; 50-64 years; 65-74 years; 75-85 years;\>85 years); of working/non-working age; employed/non-employed
Time frame: Every 12 months, up to 3 years
Plan to share: Undecided
No publications or documents are linked to this record.
Started Oct 2024 (actual). Primary completion is estimated for Dec 2027, 38 months after the start.
Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 38 months is below that.
Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation